Cargando…

Is IL-6 a key cytokine target for therapy in COVID-19?

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonist...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Simon A., Hunter, Christopher A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043092/
https://www.ncbi.nlm.nih.gov/pubmed/33850327
http://dx.doi.org/10.1038/s41577-021-00553-8